Atypical hemolytic–uremic syndrome is a genetic, life-threatening, chronic disease of complement-mediated thrombotic microangiopathy. Plasma exchange or infusion may transiently maintain normal levels ...
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into ...
Opportunities in the C5 inhibitors market include developing next-gen biosimilars and biosuperiors to improve administration frequency and expand treatment indications for diseases like aHUS, SCD, MG, ...
Researchers analyzed BTH definition, frequency, and severity across phase 3 clinical trials with terminal complement inhibitors (ravulizumab and crovalimab) and upstream complement inhibitors ...
Gefurulimab showed significant improvements in MG-ADL scores in the phase 3 PREVAIL study for anti-AChR antibody-positive gMG patients. The treatment was well tolerated, with a safety profile ...
The first-in-class oral factor D inhibitor danicopan (Voydeya) has been approved for the management of extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH). EVH affects ...
Ravulizumab (Ultomiris), a terminal complement C5 inhibitor, did not improve functional status and survival in patients with amyotrophic lateral sclerosis (ALS), the phase III CHAMPION-ALS trial ...
Recently approved treatments for generalized myasthenia gravis (gMG), including complement and neonatal Fc receptor (FcRn) inhibitors, offer a new treatment paradigm, though challenges remain. "An ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results